Peptides for Bone Healing: What Research Shows

Bone fractures heal slowly. A simple wrist fracture takes 6-8 weeks. A tibial shaft fracture can take 4-6 months. And an estimated 5-10% of fractures develop into delayed unions or non-unions, where the bone fails to heal properly at all [1].

That’s why researchers have spent decades studying whether peptides — short chains of amino acids that signal specific biological processes — can speed up bone repair. Some of this research has led to FDA-approved treatments. Much of it remains in animal studies. This guide separates what we know from what we hope.

If you’re new to peptide therapy, bone healing represents one of the more evidence-backed applications for certain peptides, particularly parathyroid hormone fragments.

Key Takeaways

Teriparatide (PTH 1-34) has the strongest clinical evidence for bone healing and is FDA-approved for osteoporosis
BPC-157 shows promising bone healing effects in animal studies but has no human clinical trial data for fractures
Growth hormone-releasing peptides (CJC-1295, ipamorelin) may support bone repair indirectly through GH/IGF-1
No peptide is FDA-approved specifically for fracture healing acceleration

How Bones Heal
Teriparatide (PTH 1-34): The Gold Standard
BPC-157 and Bone Repair
Growth Hormone Secretagogues
Other Peptides Under Investigation
What the Evidence Actually Supports
Safety Considerations
FAQ
Sources

How Bones Heal

Understanding bone healing helps explain why peptides might help — and where the gaps in evidence are.

Bone repair happens in overlapping phases:

Inflammation (days 1-7). Blood clots form at the fracture site. Immune cells clean up damaged tissue and release signaling molecules that recruit stem cells.

Soft callus formation (weeks 1-3). Cartilage forms a bridge between the broken ends. New blood vessels grow into the area. This is when the fracture becomes “sticky” but isn’t yet strong.

Hard callus formation (weeks 3-12). The cartilage is gradually replaced by woven bone through a process called endochondral ossification. Osteoblasts (bone-building cells) deposit new bone mineral.

Remodeling (months 3-24). The woven bone is slowly replaced by organized lamellar bone. The healed area gradually returns to near-normal strength.

Peptides can theoretically accelerate any of these phases — by promoting blood vessel growth, stimulating osteoblast activity, or enhancing the overall anabolic environment. The question is which ones actually do it in humans.

Teriparatide (PTH 1-34): The Gold Standard

Teriparatide is a synthetic version of the first 34 amino acids of human parathyroid hormone. It’s the peptide with the strongest evidence for bone effects, and it’s FDA-approved for osteoporosis treatment.

How It Works

When given as intermittent daily injections (as opposed to continuous exposure), PTH 1-34 paradoxically stimulates bone formation more than bone resorption. It does this by:

Increasing osteoblast number and activity
Stimulating new bone formation on both trabecular and cortical surfaces
Promoting blood vessel growth at fracture sites
Enhancing the production of growth factors like IGF-1 at the local bone level [2]

Clinical Evidence for Fracture Healing

A randomized, double-blind study of 102 postmenopausal women with distal radial (wrist) fractures compared teriparatide 20 μg/day versus placebo. The teriparatide group showed earlier cortical bridging — the time to radiographic healing was reduced from a median of 9.1 weeks to 7.4 weeks [3].

A retrospective study comparing teriparatide to bisphosphonates in osteoporotic vertebral compression fractures found that the teriparatide group had significantly faster pain relief and better vertebral body height restoration [4].

Multiple animal studies show even more dramatic effects. In rat models, daily PTH 1-34 injections increased bone mineral content, density, and torsional strength at fracture sites [5]. The systematic review by Defined et al. (2016) in BMC Medicine confirmed consistent positive effects across animal models, with human data still accumulating [5].

Current Status

Teriparatide is FDA-approved for osteoporosis (brand names Forteo and biosimilars), not specifically for fracture healing. However, orthopedic surgeons sometimes prescribe it off-label for:

Non-union fractures (bones that won’t heal)
Stress fractures in high-risk patients
Fracture healing in patients already on bisphosphonates (which can impair healing)

If you’re exploring peptide types for musculoskeletal health, PTH 1-34 sits in a unique category with actual prescription-grade evidence.

BPC-157 and Bone Repair

BPC-157 is one of the most widely discussed peptides in the recovery space, and bone healing is one of its studied applications — with an important caveat.

Animal Study Evidence

BPC-157 has demonstrated bone healing effects in multiple animal models:

In a rabbit segmental bone defect model, BPC-157 treatment significantly enhanced new bone formation compared to controls [6]
BPC-157 increased growth hormone receptor (GHR) expression in fibroblasts, which may enhance the anabolic response at injury sites [7]
The peptide promoted angiogenesis (new blood vessel formation) at fracture sites, which is critical for delivering nutrients and stem cells to healing bone [8]

The proposed mechanisms include:

VEGF upregulation — promoting blood vessel growth into the fracture callus
FAK-paxillin signaling — enhancing fibroblast and osteoblast activity
NO system modulation — improving local blood flow [8]

The Human Evidence Gap

Here’s where honesty matters: there are zero published human clinical trials studying BPC-157 specifically for bone healing. The animal data is consistent and encouraging, but animal bone healing doesn’t always translate directly to humans.

A 2025 systematic review of BPC-157 in orthopedic sports medicine noted that while preclinical studies “show its potential for promoting healing in musculoskeletal injuries such as fractures,” the lack of human trials means clinical recommendations can’t be made [9].

BPC-157 is commonly used in recovery protocols alongside other peptides. For those considering it for bone healing, the honest assessment is: theoretically promising, animal data supportive, human evidence absent.

For detailed dosing information, see our BPC-157 dosing guide.

Growth Hormone Secretagogues

Growth hormone (GH) and its downstream mediator IGF-1 play well-established roles in bone metabolism. GH-deficient individuals have reduced bone density, and GH replacement improves it. This provides the rationale for using GH-releasing peptides to support bone healing indirectly.

CJC-1295 and Ipamorelin

The CJC-1295 + ipamorelin stack is one of the most commonly prescribed peptide combinations in anti-aging and recovery medicine. By stimulating your own pituitary gland to produce more GH, these peptides raise IGF-1 levels without the supraphysiological spikes of direct GH injection.

Relevance to bone healing:

IGF-1 stimulates osteoblast differentiation and bone matrix production [10]
GH promotes callus formation during the early healing phase
Both GH and IGF-1 enhance collagen synthesis, which forms the scaffold for new bone

Evidence strength: No clinical trials have specifically tested CJC-1295 or ipamorelin for fracture healing. The rationale is based on GH/IGF-1 physiology and studies of GH replacement in GH-deficient patients. It’s a plausible mechanism, not a proven intervention for fractures.

Sermorelin

Sermorelin is another growth hormone-releasing hormone analog that works similarly. It raises GH levels modestly and physiologically. The same indirect bone-support rationale applies, with the same evidence limitations.

Other Peptides Under Investigation

Several other peptides are being studied for bone applications:

P-15 (ABM/P-15)

A synthetic 15-amino acid peptide derived from type I collagen that enhances cell attachment to bone graft materials. It’s been studied in dental implant and spinal fusion contexts, with some clinical data supporting improved bone formation when applied to graft scaffolds [11].

Osteogenic Growth Peptide (OGP)

A naturally occurring 14-amino acid peptide found in serum that stimulates osteoblast proliferation. Animal studies show enhanced fracture healing, but clinical development has been limited [5].

TP508 (Chrysalin)

A synthetic 23-amino acid peptide derived from thrombin that promotes angiogenesis and bone repair. Phase 1/2 clinical trials for distal radius fractures showed trends toward accelerated healing, but development has stalled [5].

AOD-9604

Originally studied as a fat loss peptide, AOD-9604 has shown some osteogenic activity in preclinical models. Research is too early to draw meaningful conclusions for bone healing.

What the Evidence Actually Supports

Here’s a straightforward ranking of peptides for bone healing by evidence quality:

Strong clinical evidence:

Teriparatide (PTH 1-34) — FDA-approved for osteoporosis, clinical trial data for fracture healing, widely prescribed by orthopedists

Moderate preclinical evidence:

BPC-157 — Consistent animal data showing bone healing enhancement, no human trials
P-15 — Some clinical data in dental/spinal contexts

Theoretical/indirect evidence:

CJC-1295 + ipamorelin — Based on GH/IGF-1 physiology, no fracture-specific studies
Sermorelin — Same as above
OGP, TP508 — Early research, stalled development

Insufficient evidence:

AOD-9604 for bone — Very preliminary

If you’re dealing with a fracture that’s healing slowly or not healing at all, teriparatide is the evidence-based peptide option to discuss with your orthopedist. If you’re interested in general musculoskeletal recovery support, BPC-157 and GH secretagogues are commonly used in clinical practice, but the bone-specific evidence is limited.

For a broader look at peptide options, our list of peptides covers the full range of available compounds and their applications.

Safety Considerations

Each bone-healing peptide carries different safety profiles:

Teriparatide

FDA-approved with well-characterized safety
Side effects include nausea, dizziness, leg cramps, and injection site reactions
Carries a boxed warning about osteosarcoma risk based on rat studies (high doses for near-lifetime duration), though no human cases have been attributed to teriparatide [2]
Limited to 2 years of use per current guidelines

BPC-157

Generally well-tolerated in clinical reports
No published serious adverse events in human use
Lacks formal safety data from controlled human trials
For more on BPC-157 safety, see our guide on whether peptides are safe

GH Secretagogues

Side effects can include water retention, joint stiffness, and tingling
Excessive GH elevation can worsen insulin resistance
For detailed side effect information, see our peptide side effects guide

The general principle: peptides with stronger evidence also have better-characterized safety profiles. That’s not a coincidence — it’s what clinical trials provide.

Anyone exploring peptide injections for bone healing should work with a provider who can monitor progress with imaging and adjust treatment based on response.

FAQ

Can BPC-157 help a broken bone heal faster?▼

Animal studies consistently show that BPC-157 enhances bone formation at fracture sites, likely through increased blood vessel growth and growth hormone receptor expression. However, there are no published human clinical trials confirming this effect. Some clinicians use BPC-157 as part of recovery protocols, but it’s not an evidence-based standard treatment for fractures [6, 7, 9].

What is the best peptide for bone healing?▼

Based on clinical evidence, teriparatide (PTH 1-34) has the strongest data. It’s the only peptide with human clinical trial data showing accelerated fracture healing. It’s FDA-approved for osteoporosis and sometimes used off-label for difficult fractures. BPC-157 has strong animal data but no human fracture trials [3, 5].

Does growth hormone help fractures heal?▼

GH and IGF-1 play established roles in bone metabolism, and GH-deficient patients have impaired bone healing. Studies of GH replacement show improved bone density. GH-releasing peptides like CJC-1295 and ipamorelin raise GH levels modestly, which may support healing, but no clinical trials have specifically tested them for fracture repair [10].

How long does it take for peptides to help with bone healing?▼

Teriparatide clinical data showed measurable acceleration of wrist fracture healing — median time to cortical bridging decreased from 9.1 weeks to 7.4 weeks. For other peptides without human fracture data, timelines are speculative. Bone healing is inherently slow regardless of intervention [3].

Are peptides for bone healing FDA-approved?▼

Teriparatide is FDA-approved for osteoporosis treatment, not specifically for fracture healing (though it’s sometimes used off-label for this). No other peptide is FDA-approved for bone healing or fracture repair. BPC-157, CJC-1295, ipamorelin, and other peptides used in clinical practice are prescribed through compounding pharmacies.

Sources

Einhorn TA, Gerstenfeld LC. Fracture healing: mechanisms and interventions. Nat Rev Rheumatol. 2015;11(1):45-54. PubMed
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441. PubMed
Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404-414. PubMed
Kim MH, Lee AS, Min SH, Yoon SH. Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture. Asian Spine J. 2017;11(1):68-76. PMC
Defined S, et al. The role of peptides in bone healing and regeneration: a systematic review. BMC Med. 2016;14:103. PMC
Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972-1989. PubMed
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. PMC
Sikiric P, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Pharm Des. 2025. PMC
Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Am J Sports Med. 2025. PMC
Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29(5):535-559. PubMed
Yukna RA, Callan DP, Krauser JT, et al. Multi-center clinical evaluation of combination anorganic bovine-derived hydroxyapatite matrix (ABM)/cell binding peptide (P-15) as a bone replacement graft material in human periodontal osseous defects. J Periodontol. 2001;72(10):1424-1430. PubMed